Mandy Klass, MD
Family Medicine · Glandorf, OHNPI 1235135260
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 91.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $3,848 and has fallen 97.0% since, to $117 in 2025.
Across 32 payments — averaging $130.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Novo Nordisk$66
- Abbott$62
- AbbVie$44
- Lilly USA, LLC$39
- Exact Sciences$23
- plus $115 from 7 others
What the payments were for
- Consulting fees$2,29655%
- Travel & lodging$1,24030%
- Food & beverage$63715%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 12 | $3,824 |
| Novo Nordisk | 4 | $66 |
| Abbott | 3 | $62 |
| AbbVie | 3 | $44 |
| Lilly USA, LLC | 2 | $39 |
| Exact Sciences | 1 | $23 |
| AstraZeneca | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Madrigal Pharmaceuticals | 1 | $18 |
| Dexcom, Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Pfizer | 1 | $14 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$3,680
How this compares
$4,173 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 232 | $204,786 |
| MounjaroTirzepatide | 128 | $169,683 |
| TrulicityDulaglutide | 121 | $150,985 |
| Repatha SureclickEvolocumab | 61 | $89,337 |
| OzempicSemaglutide | 51 | $85,979 |
| XareltoRivaroxaban | 75 | $75,493 |
| JanuviaSitagliptin Phosphate | 68 | $64,328 |
| JardianceEmpagliflozin | 52 | $52,458 |
| FarxigaDapagliflozin Propanediol | 50 | $51,223 |
| RybelsusSemaglutide | 32 | $49,611 |
| Bydureon BciseExenatide Microspheres | 23 | $26,557 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $25,729 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $24,885 |
| MyrbetriqMirabegron | 43 | $21,043 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 88 | $19,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $39 | $320,668249 claims |
| PfizerEliquis, Paxlovid | $14 | $211,580256 claims |
| Novo NordiskOzempic, Rybelsus | $66 | $135,59083 claims |
| AstraZenecaFarxiga, Brilinta | $19 | $64,35565 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $18,31734 claims |
| AbbVieRestasis | $44 | $6,53614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Glandorf
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
- David NeidhardtLima$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.